Oligoastrocytic tumor

Oligoastrocytic tumor, also known as oligoastrocytoma or mixed oligoastrocytoma, is a rare brain tumor that historically was classified as a distinct type of diffuse glioma containing a mixture of two different glial cell types: oligodendrocytes and astrocytes. These tumors arise within the central nervous system, most commonly in the cerebral hemispheres, particularly the frontal and temporal lobes. They were previously graded as either WHO grade II (low-grade) or WHO grade III (anaplastic oligoastrocytoma), depending on the degree of malignancy. Key symptoms depend on tumor location and size but commonly include seizures, headaches, cognitive changes, personality or behavioral alterations, focal neurological deficits such as weakness or speech difficulties, and signs of increased intracranial pressure including nausea and vomiting. Seizures are frequently the presenting symptom, particularly in lower-grade tumors. It is important to note that the 2016 and subsequent WHO Classifications of Tumors of the Central Nervous System have largely eliminated oligoastrocytoma as a distinct diagnostic entity. Advances in molecular diagnostics, particularly testing for IDH mutations and 1p/19q codeletion status, have shown that most tumors previously classified as mixed oligoastrocytomas can be reclassified as either oligodendrogliomas or astrocytomas based on their molecular profile. Treatment historically included surgical resection, radiation therapy, and chemotherapy (often with temozolomide or PCV regimen), with the specific approach guided by tumor grade, molecular markers, and patient factors. Prognosis varies considerably depending on grade, molecular characteristics, extent of resection, and patient age.

Common questions about Oligoastrocytic tumor